AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21787456 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley porridge with 16 g/100 g fibre content
Number of subjects: 10
Study 21787456 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley porridge with 10 g/100 g fibre content
Number of subjects: 10
Study 21787456 — intervention group
Group type: COMPARATOR
Intervention: Reference glucose
Number of subjects: 10
Study 20530281 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin (DP) chemotherapy with concurrent thoracic radiotherapy (TRT)
Number of subjects: 200
Study 20530281 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin, vindesine, and cisplatin (MVP) chemotherapy with concurrent TRT
Number of subjects: 200
Study 20530281 — intervention group
Group type: COMPARATOR
Intervention: MVP arm
Number of subjects: 200
Study 20530281 — intervention group
Group type: EXPERIMENTAL
Intervention: DP arm
Number of subjects: 200
Study 17949578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ericksonian hypnosis (EH)
Number of subjects: 43
Study 17949578 — intervention group
Group type: COMPARATOR
Intervention: Sham-hypnosis (SH)
Number of subjects: 43
Study 15613140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 17
Study 15613140 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 17
Study 12039615 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic analgesic nitrous oxide (PAN)
Number of subjects: 23
Study 12039615 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepine (diazepam)
Number of subjects: 23
Study 10022628 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-infusion
Number of subjects: 34
Study 10022628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine-infusion
Number of subjects: 34
Study 10022628 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-injection
Number of subjects: 34
Study 10022628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine-injection
Number of subjects: 34
Study 7595265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy consultation
Number of subjects: 56
Study 7595265 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 56
Study 2260432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 63
Study 2260432 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 63
Study 7411122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lists of six colored Xs
Number of subjects: 60
Study 7411122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lists of six colored words
Number of subjects: 60
Study 7411122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lists of six color names printed in incongruent colors
Number of subjects: 60
Study 31496045 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 31496045 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study 30864090 — intervention group
Group type: EXPERIMENTAL
Intervention: Kedo-S rotary files
Number of subjects: 69
Study 30864090 — intervention group
Group type: COMPARATOR
Intervention: K-file
Number of subjects: 69
Study 30864090 — intervention group
Group type: COMPARATOR
Intervention: H-file
Number of subjects: 69
Study 28267900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Ledipasvir (LDV) for 12 weeks
Number of subjects: 14
Study 28267900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Ledipasvir (LDV)
Number of subjects: 14
Study 28267900 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir (SOF) + Ribavirin (RBV)
Number of subjects: 14
Study 25830404 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (test group)
Number of subjects: 34
Study 25830404 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading (control group)
Number of subjects: 34
Study 24148799 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes of simple advice on reducing alcohol consumption
Number of subjects: 154
Study 24148799 — intervention group
Group type: COMPARATOR
Intervention: No advice about drinking (Control)
Number of subjects: 154
Study 21269302 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal blood pumps (e.g., Rotaflow, Bio-Medicus)
Number of subjects: 240
Study 21269302 — intervention group
Group type: COMPARATOR
Intervention: Roller pumps (e.g., Roller, Avecor, Sarns)
Number of subjects: 240
Study 19675446 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 units subcutaneous on postoperative days 1 and 7)
Number of subjects: 40
Study 16806042 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyboard with an opening angle of 12 degrees, a gable angle of 14 degrees, and a slope of 0 degrees
Number of subjects: 100
Study 16806042 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyboard with a gable angle of 8 degrees
Number of subjects: 100
Study 16806042 — intervention group
Group type: COMPARATOR
Intervention: Conventional laptop keyboard
Number of subjects: 100
Study 16806042 — intervention group
Group type: EXPERIMENTAL
Intervention: All 6 keyboard configurations
Number of subjects: 100
Study 15170918 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone pulse therapy (MPPT) - 1000 mg IV for 3 alternate days, mean interval of 76 days for one year.
Number of subjects: 31
Study 15170918 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone (OMP) - continuous therapy.
Number of subjects: 31
Study 11482501 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard filter with longer hollow fibers
Number of subjects: 24
Study 9663183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine administered over a 24‐hour period every 2 to 3 weeks for 6 months.
Number of subjects: 19
Study 9663183 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered over a 24‐hour period every 2 to 3 weeks for 6 months.
Number of subjects: 19
Study 9663183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine and placebo groups.
Number of subjects: 19
Study 8310987 — intervention group
Group type: EXPERIMENTAL
Intervention: S (shea butter; 42% stearic acid)
Number of subjects: 15
Study 2956297 — intervention group
Group type: EXPERIMENTAL
Intervention: Elase solution
Number of subjects: 34
Study 2956297 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) solution
Number of subjects: 34
Study 29709235 — intervention group
Group type: EXPERIMENTAL
Intervention: MDH2008 protocol (adapted to therapeutic response to 2 cycles of chemotherapy)
Number of subjects: 444
Study 29709235 — intervention group
Group type: EXPERIMENTAL
Intervention: MDH2008 protocol
Number of subjects: 444
Study 27565841 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 27565841 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 25555109 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismus surgery
Number of subjects: 97
Study 23614743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum extract rich in hyperforin cream
Number of subjects: 11
Study 23614743 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 11
Study 16343236 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m², Carboplatin AUC 5, Gemcitabine 800 mg/m² on day 1 and 800 mg/m² on day 8, every 3 weeks for six courses (TCG regimen)
Number of subjects: 1742
Study 16343236 — intervention group
Group type: COMPARATOR
Intervention: Standard TC regimen (175 mg/m² 3 h/AUC 5 day 1 q 21 x 6)
Number of subjects: 1742
Study 16343236 — intervention group
Group type: EXPERIMENTAL
Intervention: TCG regimen
Number of subjects: 1742
Study 12598738 — intervention group
Group type: EXPERIMENTAL
Intervention: Active phone exposure
Number of subjects: 62
Study 12598738 — intervention group
Group type: COMPARATOR
Intervention: Inactive phone exposure
Number of subjects: 62
Study 12598738 — intervention group
Group type: COMPARATOR
Intervention: No phone exposure
Number of subjects: 62
Study 10633302 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0
Study 10633302 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 7864415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral meperidine (3 mg/kg) with pentobarbital (4 mg/kg)
Number of subjects: 58
Study 7864415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal ketamine (5 mg/kg) with midazolam (0.2 mg/kg)
Number of subjects: 58
Study 7864415 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal methohexital (30 mg/kg)
Number of subjects: 58
Study 1950542 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of allergen
Number of subjects: 16
Study 1950542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1950542 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen (any dose)
Number of subjects: 16
Study 1950542 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil cationic protein (ECP) levels
Number of subjects: 16
Study 1950542 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophils or ECP levels
Number of subjects: 16
Study 7020738 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan treatment
Number of subjects: 293
Study 7020738 — intervention group
Group type: COMPARATOR
Intervention: Radiophosphorus therapy
Number of subjects: 293
Study 31923924 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-based physical activity program
Number of subjects: 50
Study 31923924 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 31242910 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarf osteotomy with Akin osteotomy (group SA)
Number of subjects: 247
Study 31242910 — intervention group
Group type: COMPARATOR
Intervention: Scarf osteotomy without Akin osteotomy (group S)
Number of subjects: 247
Study 28450194 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored self-management resources
Number of subjects: 214
Study 28450194 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 25921348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) in patients with baseline PR interval ≥180 ms
Number of subjects: 87
Study 25921348 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) in patients with baseline PR interval <180 ms
Number of subjects: 87
Study 23537492 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention with standard exercise and nutrition information plus up to five face-to-face MI sessions over 6 months.
Number of subjects: 0
Study 23537492 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard exercise and nutrition information only.
Number of subjects: 0
Study 23537492 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention.
Number of subjects: 0
Study 23537492 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard information only.
Number of subjects: 0
Study 21548660 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat 200 mg after fasting
Number of subjects: 12
Study 21548660 — intervention group
Group type: COMPARATOR
Intervention: Etamicastat 200 mg after a high-fat meal
Number of subjects: 12
Study 21548660 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat (fasting)
Number of subjects: 12
Study 18208875 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) therapy
Number of subjects: 46
Study 16478838 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (80 microg/4.5 microg, two inhalations qd)
Number of subjects: 697
Study 16478838 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (160 microg, two inhalations qd) plus terbutaline (0.4 mg) as needed
Number of subjects: 697
Study 16478838 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 697
Study 12790763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosulepine (25‐125 mg daily for 4‐8 weeks)
Number of subjects: 18
Study 11177202 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil (PO)
Number of subjects: 18
Study 11177202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil (SO)
Number of subjects: 18
Study 11177202 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (OO)
Number of subjects: 18
Study 11177202 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO)
Number of subjects: 18
Study 11177202 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meals (LF)
Number of subjects: 18
Study 9296413 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lung collapse (TLC) plus 5 cm H2O of CPAP for 15 mins, followed by selective lobe collapse plus 5 cm H2O of CPAP (Group 1)
Number of subjects: 30
Study 9296413 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective lobar collapse plus 5 cm H2O of CPAP (Group 2)
Number of subjects: 30
Study 9296413 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lung collapse without CPAP (Group 3)
Number of subjects: 30
Study 9296413 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective lobe collapse without CPAP (Group 4)
Number of subjects: 30
Study 9296413 — intervention group
Group type: COMPARATOR
Intervention: All groups (Group 1, Group 2, Group 3, Group 4)
Number of subjects: 30
Study 8400098 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP) 0.3 microgram/kg of body weight
Number of subjects: 40
Study 8400098 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study 3755376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyaluronidase
Number of subjects: 9
Study 3755376 — intervention group
Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt
Number of subjects: 9
Study 31440909 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal cueing during swallowing
Number of subjects: 25
Study 31440909 — intervention group
Group type: COMPARATOR
Intervention: Non-cued swallowing (unprompted)
Number of subjects: 25
Study 29599173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubridge flow diverter implantation
Number of subjects: 185
Study 29599173 — intervention group
Group type: COMPARATOR
Intervention: Enterprise stent-assisted coiling
Number of subjects: 185
Study 27692669 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery (SCS)
Number of subjects: 201
Study 24111492 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 124
Study 22423894 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural tension technique (NTT)
Number of subjects: 10
Study 22423894 — intervention group
Group type: COMPARATOR
Intervention: Random passive movements (RPM)
Number of subjects: 10
Study 20970066 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 75
Study 20970066 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 75
Study 18687165 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (valsartan 160 mg + hydrochlorothiazide 12.5 mg)
Number of subjects: 1313
Study 18687165 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 1313
Study 18687165 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 1313
Study 16841677 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue (YQHX) method
Number of subjects: 80
Study 16841677 — intervention group
Group type: COMPARATOR
Intervention: Yiqi (YQ) method
Number of subjects: 80
Study 16841677 — intervention group
Group type: COMPARATOR
Intervention: Huoxue (HX) method
Number of subjects: 80
Study 16841677 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 80
Study 12814457 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily
Number of subjects: 20
Study 12814457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10642740 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion imaging in MS patients with cord lesions
Number of subjects: 10
Study 10642740 — intervention group
Group type: COMPARATOR
Intervention: Diffusion imaging in healthy volunteers (control)
Number of subjects: 10
Study 8638794 — intervention group
Group type: EXPERIMENTAL
Intervention: C8-T2 epidural analgesia
Number of subjects: 8
Study 8638794 — intervention group
Group type: EXPERIMENTAL
Intervention: C3-4 epidural analgesia
Number of subjects: 8
Study 8638794 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 8
Study 1762385 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) 80 mmol K+ daily
Number of subjects: 42
Study 1762385 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate/bicarbonate (K-cit/bic) 80 mmol K+ daily
Number of subjects: 42
Study 1762385 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl)
Number of subjects: 42
Study 6573315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 0.25 g
Number of subjects: 10
Study 6573315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 0.5 g
Number of subjects: 10
Study 6573315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 1.0 g
Number of subjects: 10
Study 6573315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 2.0 g
Number of subjects: 10
Study 6573315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (all doses)
Number of subjects: 10
Study 30893392 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol propionate lotion 0.01%
Number of subjects: 430
Study 30893392 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 430
Study 28099220 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Number of subjects: 0
Study 28099220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26487393 — intervention group
Group type: EXPERIMENTAL
Intervention: Training as usual supplemented by change agent interactions after the training
Number of subjects: 57
Study 26487393 — intervention group
Group type: COMPARATOR
Intervention: Training as usual
Number of subjects: 57
Study 25091662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral monovalent rotavirus vaccine
Number of subjects: 6799
Study 25091662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6799
Study 22071987 — intervention group
Group type: EXPERIMENTAL
Intervention: LTW fiber
Number of subjects: 120
Study 22071987 — intervention group
Group type: EXPERIMENTAL
Intervention: STW fiber
Number of subjects: 120
Study 22071987 — intervention group
Group type: COMPARATOR
Intervention: SF fiber
Number of subjects: 120
Study 19659407 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based osteoporosis clinic with monthly telephone follow-up
Number of subjects: 211
Study 19659407 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by primary care physician
Number of subjects: 211
Study 17627092 — intervention group
Group type: EXPERIMENTAL
Intervention: Valtropin
Number of subjects: 147
Study 17627092 — intervention group
Group type: COMPARATOR
Intervention: Humatrope
Number of subjects: 147
Study 15066665 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (2 x 100 mg once daily for 10 days)
Number of subjects: 13
Study 15066665 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 13
Study 11448393 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials with negative results
Number of subjects: 90
Study 10448637 — intervention group
Group type: EXPERIMENTAL
Intervention: MDF treatment (5 times over 21 weeks)
Number of subjects: 20
Study 10448637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 10448637 — intervention group
Group type: EXPERIMENTAL
Intervention: MDF treatment
Number of subjects: 20
Study 10448637 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 7829640 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH-(1-34)
Number of subjects: 10
Study 7829640 — intervention group
Group type: COMPARATOR
Intervention: hPTHrP-(1-34)
Number of subjects: 10
Study 2241185 — intervention group
Group type: EXPERIMENTAL
Intervention: YNK01 single administration (800 mg/body/day)
Number of subjects: 0
Study 2241185 — intervention group
Group type: EXPERIMENTAL
Intervention: YNK01 5-day administration (300 mg/body/day)
Number of subjects: 0
Study 2241185 — intervention group
Group type: EXPERIMENTAL
Intervention: YNK01 5-day administration (500 mg/body/day)
Number of subjects: 0
Study 2241185 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day administration of YNK01
Number of subjects: 0
Study 2241185 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of YNK01
Number of subjects: 0
Study 332370 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent coronary bypass surgery
Number of subjects: 42
Study 332370 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy
Number of subjects: 42
Study 28002091 — intervention group
Group type: EXPERIMENTAL
Intervention: WFG-PRK with the VISX CustomVue Star S4 IR
Number of subjects: 71
Study 28002091 — intervention group
Group type: COMPARATOR
Intervention: WFO-PRK with the Wavelight Allegretto Eye‐Q 400‐Hz laser platform
Number of subjects: 71
Study 27739091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (0.04 g/dl)
Number of subjects: 120
Study 27739091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 27739091 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose alcohol (0.065 g/dl)
Number of subjects: 120
Study 24608203 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors
Number of subjects: 9
Study 24608203 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 9
Study 22938728 — intervention group
Group type: EXPERIMENTAL
Intervention: AgTive silver-nanoparticle-impregnated CVCs (SC)
Number of subjects: 338
Study 22938728 — intervention group
Group type: COMPARATOR
Intervention: Conventional CVCs (CC)
Number of subjects: 338
Study 20512065 — intervention group
Group type: COMPARATOR
Intervention: Dynamic warm-up with no external resistance (control condition)
Number of subjects: 20
Study 20512065 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic warm-up with weighted vest (5%, 10%, 15%, or 20% of body weight)
Number of subjects: 20